BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 19056693)

  • 41. miR-130b and miR-128a are essential lineage-specific codrivers of t(4;11) MLL-AF4 acute leukemia.
    Malouf C; Antunes ETB; O'Dwyer M; Jakobczyk H; Sahm F; Landua SL; Anderson RA; Soufi A; Halsey C; Ottersbach K
    Blood; 2021 Nov; 138(21):2066-2092. PubMed ID: 34111240
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The leukemia-associated Mll-Ell oncoprotein induces fibroblast growth factor 2 (Fgf2)-dependent cytokine hypersensitivity in myeloid progenitor cells.
    Shah CA; Bei L; Wang H; Platanias LC; Eklund EA
    J Biol Chem; 2013 Nov; 288(45):32490-32505. PubMed ID: 24089521
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Meningioma 1 is indispensable for mixed lineage leukemia-rearranged acute myeloid leukemia.
    Sharma A; Jyotsana N; Gabdoulline R; Heckl D; Kuchenbauer F; Slany RK; Ganser A; Heuser M
    Haematologica; 2020 May; 105(5):1294-1305. PubMed ID: 31413090
    [TBL] [Abstract][Full Text] [Related]  

  • 44. t(4;11) leukemias display addiction to MLL-AF4 but not to AF4-MLL.
    Kumar AR; Yao Q; Li Q; Sam TA; Kersey JH
    Leuk Res; 2011 Mar; 35(3):305-9. PubMed ID: 20869771
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The stem cell-specific long noncoding RNA HOXA10-AS in the pathogenesis of KMT2A-rearranged leukemia.
    Al-Kershi S; Bhayadia R; Ng M; Verboon L; Emmrich S; Gack L; Schwarzer A; Strowig T; Heckl D; Klusmann JH
    Blood Adv; 2019 Dec; 3(24):4252-4263. PubMed ID: 31867596
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An aberrantly sustained emergency granulopoiesis response accelerates postchemotherapy relapse in
    Wang H; Shah CA; Hu L; Huang W; Platanias LC; Eklund EA
    J Biol Chem; 2020 Jul; 295(28):9663-9675. PubMed ID: 32467231
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MicroRNA-155 is upregulated in MLL-rearranged AML but its absence does not affect leukemia development.
    Schneider E; Staffas A; Röhner L; Krowiorz K; Heuser M; Döhner K; Bullinger L; Döhner H; Fogelstrand L; Rouhi A; Kuchenbauer F; Palmqvist L
    Exp Hematol; 2016 Dec; 44(12):1166-1171. PubMed ID: 27619068
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential.
    Wong P; Iwasaki M; Somervaille TC; So CW; Cleary ML
    Genes Dev; 2007 Nov; 21(21):2762-74. PubMed ID: 17942707
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HOX expression patterns identify a common signature for favorable AML.
    Andreeff M; Ruvolo V; Gadgil S; Zeng C; Coombes K; Chen W; Kornblau S; Barón AE; Drabkin HA
    Leukemia; 2008 Nov; 22(11):2041-7. PubMed ID: 18668134
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HOXA9 and MEIS1 gene overexpression in the diagnosis of childhood acute leukemias: Significant correlation with relapse and overall survival.
    Adamaki M; Lambrou GI; Athanasiadou A; Vlahopoulos S; Papavassiliou AG; Moschovi M
    Leuk Res; 2015 Aug; 39(8):874-82. PubMed ID: 26059450
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A role for MEIS1 in MLL-fusion gene leukemia.
    Kumar AR; Li Q; Hudson WA; Chen W; Sam T; Yao Q; Lund EA; Wu B; Kowal BJ; Kersey JH
    Blood; 2009 Feb; 113(8):1756-8. PubMed ID: 19109563
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia.
    Zhou B; Qin Y; Zhou J; Ruan J; Xiong F; Dong J; Huang X; Yu Z; Gao S
    J Cell Mol Med; 2021 Mar; 25(6):3124-3135. PubMed ID: 33599085
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16.
    Ueda K; Yoshimi A; Kagoya Y; Nishikawa S; Marquez VE; Nakagawa M; Kurokawa M
    Cancer Sci; 2014 May; 105(5):512-9. PubMed ID: 24612037
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia.
    Wei J; Wunderlich M; Fox C; Alvarez S; Cigudosa JC; Wilhelm JS; Zheng Y; Cancelas JA; Gu Y; Jansen M; Dimartino JF; Mulloy JC
    Cancer Cell; 2008 Jun; 13(6):483-95. PubMed ID: 18538732
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1.
    Juszczynski P; Rodig SJ; Ouyang J; O'Donnell E; Takeyama K; Mlynarski W; Mycko K; Szczepanski T; Gaworczyk A; Krivtsov A; Faber J; Sinha AU; Rabinovich GA; Armstrong SA; Kutok JL; Shipp MA
    Clin Cancer Res; 2010 Apr; 16(7):2122-30. PubMed ID: 20332322
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Flt3 does not play a critical role in murine myeloid leukemias induced by MLL fusion genes.
    Albouhair S; Morgado E; Lavau C
    PLoS One; 2013; 8(8):e72261. PubMed ID: 23977266
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Heritable genetic background alters survival and phenotype of Mll-AF9-induced leukemias.
    Young K; Loberg MA; Eudy E; Schwartz LS; Mujica KD; Trowbridge JJ
    Exp Hematol; 2020 Sep; 89():61-67.e3. PubMed ID: 32768438
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
    Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Insights from clinical studies into the role of the MLL gene in infant and childhood leukemia.
    Chowdhury T; Brady HJ
    Blood Cells Mol Dis; 2008; 40(2):192-9. PubMed ID: 17905612
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inactivation of PBX3 and HOXA9 by down-regulating H3K79 methylation represses NPM1-mutated leukemic cell survival.
    Zhang W; Zhao C; Zhao J; Zhu Y; Weng X; Chen Q; Sun H; Mi JQ; Li J; Zhu J; Chen Z; Pandolfi PP; Chen S; Yan X; Xu J
    Theranostics; 2018; 8(16):4359-4371. PubMed ID: 30214626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.